Shahin Akhondzadeh

Professor of Neuroscience

Tell :

Fax :

Email :

---

SHAHIN AKHONDZADEH-BASTI

Qualification: Pharm.D., Ph.D., FBPharmacolS., D.Sc.

Marital status: Married (one child)

Date of birth: March 21, 1968

Address:

Home (Address for correspondence):

No: 29, 39th Street, Gisha Street

Tehran 14479, IRAN.

Tel: +21 - 88281866

Fax: +21 - 55419113

E.mail: s.akhond@neda.net

Work:

Roozbeh Psychiatric Hospital

Tehran University of Medical Sciences

South Kargar Street

Tehran 13337, Iran

Tel: +21-55412222

Fax: +21-55419113

E.mail: s.akhond@neda.net

E.mail: sakhond@yahoo.com

Homepage: http://www.tums.ac.ir/faculties/s.akhond

Education:

1- Tehran University of Medical Sciences, Iran, Doctor of Pharmacy (Pharm.D.) 1985-1991.

Thesis: The Interaction of GABA and Dopamine on Stereotype Behavior.

2- Division of Neuroscience and Biomedical Systems, IBLS, Faculty of Medicine, Glasgow

University, Glasgow, UK, Ph.D. (Neuroscience) (April 21, 1993 - July 8, 1995).

Thesis: Studies of Adenosine and GABAA Receptors in Hippocampal Slices.

3- Fellowship, Unit 29 (Research in Epilepsy), INSERM, PARIS, FRANCE (1999).

Work Experience:

1- Senior Advisor of President. Welfare Organization, Tehran. Iran (1991 - 1992).

2- Professor of Clinical Neuropsychopharmacology (Teaching Clinical Psychopharmacology,

Neuroscience and Substance Dependence to Medical Students and Residents of Psychiatry) Roozbeh

Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran (since August 1, 1995).

3- Director, Research Unit, Roozbeh Psychiatric Hospital, Tehran, Iran (August 1, 1995 -1996).

4- Assistant Professor, Neurosciences. Brain Research Institute. Niigata University. Niigata, Japan (1996-1997).

5- Deputy for research, National Research Center of Medical Sciences, Tehran, Iran (2001-2002)

6- Director, Institute of Medicinal Plants, Tehran, Iran (1999-2004)

7- Editor in Chief, Journal of Medicinal Plants (in Persian), Tehran, Iran (2001-2004)

8- Deputy for Research, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran (2002-2004).

9- Editor in Chief, Iranian Journal of Diabetes and Lipid Disorders (in Persian), Tehran, Iran (2002-2005)

10- Advisor of President of Iranian Red Crescent for research affairs (since 2002)

11- Director General, International Affairs, Tehran University of Medical Sciences (2003-2005)

12- Associate Editor, Archive of Iranian Medicine (in English), Tehran, Iran (since 2004)

13- Editor in Chief, Medical Journal of Iranian Red Crescent (in English), Dubai, UAE (since 2004)

14- Vice dean for research, faculty of medicine, Tehran University of Medical Sciences, Tehran, Iran

(since 2005)

15- Deputy for Research, Psychiatry and clinical psychology research institute, Roozbeh Psychiatric

Hospital, Tehran University of Medical Sciences, Tehran, Iran (since 2005).

16- Deputy Editor, Iranian Journal of Psychiatry (in English) (since 2005)

Social & Scientific Activity:

Fellow of British Pharmacological Society (FBPharmacolS) (clinical section)

Member of Scottish Neuroscience Group

Member of General Council of Glasgow University

Achievements:

To obtain Ph.D. degree in neuroscience with first class just in two years in Glasgow University.

RAZI Award (national) for the best researcher in clinical sciences, Tehran, Iran (2000).

Avisina Award (Tehran University of Medical Sciences) for publications in international journals,

Tehran, Iran (2002).

Avisina Award (Tehran University of Medical Sciences) for Highly Cited Paper, Tehran, Iran (2005).

Referee of International Scientific Journals:

Addiction

Journal of Clinical Pharmacy and Therapeutics

BMC Pharmacology

BMC Alternative and Complementary Medicine

Journal of Neurology, Neurosurgery and Psychiatry

Nutrition

Psychiatric Research

Current Drug Therapy

Expert Review in Neurotherapeutics

Progress in Neuropsychopharmacology and Biological Psychiatry

Behavioural Brain Research

Schizophrenia Research

Psychopharmacology

Clinical Psychopharmacology

Biological Psychiatry

Editorial Board of International Journals:

Journal of Psychiatric Intensive Care

International Medical Case Reports Journal

Journal of Therapeutics and Clinical Risk Management

International Journal of Biomedical Sciences

Journal of Medical Sciences

Trends in Medical Research

Archives of Iranian Medicine

Iranian Journal of Asthma and Allergy

Tehran Heart Journal

Interests:

Wrestling, fishing and music

Research Interests:

* The role of GABAA receptors in the synaptic plasticity and cognition

* The Glutamate, 5-HT and Adenosine hypotheses of schizophrenia

* Indirect modulators of dopamine receptors

* Pharmacotherapy in psychiatry including schizophrenia, bipolar disorder, depression, OCD, ADHD and autism

* Pharmacotherapy of addiction

* Negative modulators of GABAA receptors in the treatment of dementia

Publications:

A. Papers

1- AKHONDZADEH, S. & STONE, T.W. (1994). Interaction between adenosine and GABAA receptors on hippocampal neurons, Brain Res., 665, 229-236.

2- AKHONDZADEH, S. & STONE, T.W. (1995). Potentiation by neurosteroids of muscimol/adenosine interaction in rat hippocampus. Brain Res., 677, 311-318.

3- AKHONDZADEH, S. & STONE, T.W. (1995). Induction of a novel form of hippocampal longterm depression by muscimol: Involvement of GABAA but not glutamate receptors. Br. J. Pharmacol., 115, 527-533.

4- AKHONDZADEH. S. & STONE, T.W. (1996). Glutamate-independent long-term depression in rat hippocampus by activation of GABAA receptors. Life Science., 58, 1023-1030.

5- AKHONDZADEH. S. & STONE, T.W. (1996). Muscimol-induced long-term depression in the hippocampus: Lack of dependence on extracellular calcium. Neuroscience., 71, 581-588.

6- AKHONDZADEH, S. & STONE, T.W. (1996). Maintenance of muscimol-induced long-term depression by neurosteroids. Prog. Neuro-Psychopharmacology and Biological Psychiatry., 20, 277-289.

7- NOORBALA A.A., HOSSEINI S.H., MOHAMMADI M.R. & AKHONDZADEH. S. (1998). Combination of clomipramine and nortriptyline in the treatment of obsessive-compulsive disorder: a double-blind, placebo-controlled study. Journal of Clinical Pharmacy and Therapeutics., 23, 155-159.

8- AKHONDZADEH. S. & STONE, T.W. (1998). Potentiation of Muscimol-induced long-term depression by benzodiazepines and prevention or reversal by pregnenolone sulfate. Pharmacological Research., 38, 441-448.

9- AKHONDZADEH. S. & STONE, T.W. (1999). Prevention of muscimol-induced long-term depression by brain-derived neurotrophic factor. Progress in Neuropsychopharmacology and Biological Psychiatry., 23, 1215-1226.

10- AKHONDZADEH S., EMAMIAN. E., ABHARI. S.A. & SHABESTARI. O. (1999). Is it time to have another look at lithium in bipolar disorder? Progress in Neuropsychopharmacology and Biological Psychiatry., 23, 1011-1117.

11- NOORBALA A.A., AKHONDZADEH S., DAVARI-ASHTINAI R. & AMINI-NOOSHABADI H. (1999). Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. Journal of Clinical Pharmacy and Therapeutics., 24, 369-374.

12- AKHONDZADEH S., MOHAMMADI M.A., AMINI-NOOSHABADI H. & DAVARIASHTIANI R. (1999). Cyproheptadine in treatment of chronic schizophrenia: a double-blind, placebocontrolled study. Journal of Clinical Pharmacy and Therapeutics., 24, 49-52.

13- AKHONDZADEH S., SHASAVAND E., JAMILIAN H.R., SHABESTARI O. and KAMALIPOUR A. (2000). Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interaction. Journal of Clinical Pharmacy and Therapeutics., 25, 131-138.

14- AKHONDZADEH S., AHMADI-ABHARI S.A., ASSADI S.M., SHABESTARI O.L, KASHANI A.R. and FARZANEHGAN, Z.M. (2000). Double-blind randomized controlled trial of baclofen in the treatment of opiates withdrawal. Journal of Clinical Pharmacy and Therapeutics., 25, 347-353.

15- AHMADI-ABHARI S.A., AKHONDZADEH S., ASSADI S.M., SHABESTARI O.L, FARZANEHGAN, Z.M. and A. Kamalipour (2001). Baclofen versus clonidine in the treatment of opiates withdrawal, side effects aspect: A double blind randomized controlled trial. Journal of Clinical Pharmacy and Therapeutics., 26, 67-71.

16- AKHONDZADEH S., NAGHAVI H.R., VAZIRIAN M., SHAYEGANPOUR A., RASHIDI H. and KHANI M. (2001). Passionflower in the treatment of generalized anxiety: A double-blind and randomized trial with oxazepam. Journal of Clinical Pharmacy and Therapeutics., 26, 363-367.

17- AKHONDZADEH S., KASHANI L., MOBASSERI M., HOSSEINI S.H., NIKZAD S. and KHANI M. (2001). Passionflower in the treatment of opiates withdrawal: A double-blind and randomized trial. Journal of Clinical Pharmacy and Therapeutics., 26, 368-373.

18- GUDARZI S., YASAMYM. and AKHONDZADEH S. (2002). Cyproheptadine in the treatment of autism. Eur. Psychiatry. 17, 230-231.

19- AKHONDZADEH S., MOJTAHEDZADEH V. MIRSEPASSI G.R. and KAMILIPOUR A. (2002). Diazoxide in the treatment of schizophrenia: a novel application of potassium channel openers in the CNS disorders. J. Clinical Pharmacy and Therapeutics. 27, 453-459.

20- AKHONDZADEH S. MOHAMMADI M.R. & KHASHANI, L. (2002). Potentiation of Muscimolinduced long-term depression by benzodiazepines but not zolpidem. Progress in Neuropsychopharmacology and Biological Psychiatry 26, 1161-1166.

21- AKHONDZADEH S. KASHANI L. FOTOUHI A. JARVANDI S. et al. (2003). Comparison of Lavandula angostofolia Mill. tincture and imipramine in the treatment of mild to moderate depression: a double-blind, randomized pilot study. Progress in Neuropsychopharmacology and Biological Psychiatry 27, 123-127.

22- AKHONDZADEH S., TAVAKOLIAN R., DAVARI-ASHTIANI R., ARABGOL F. and AMININOOSHABADI H. (2003). Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind randomized and controlled trial. Progress in Neuropsychopharmacology and Biological Psychiatry 27, 452-458.

23- AKHONDZADEH S., NOROOZIAN M., MOHAMMADI M., OHADINIA S., JAMSHIDI A. and KHANI M. (2003). Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics. 28, 53-59.

24- AKHONDZADEH S., NOROOZIAN M., MOHAMMADI M., OHADINIA S., JAMSHIDI A. and KHANI M. (2003). Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double blind, randomized and placebo-controlled trial. Journal of Neurology, Neurosurgery and Psychiatry 74, 863-6.

25- AKHONDZADEH S., NEJATISAFA AK., AMINI H., LARIJANI B., KASHANI L., RAISI F. and KAMALIPOUR A. (2003).Adjunctive estrogen treatment in women with chronic schizophrenia: a double blind, randomized and placebo controlled trial. Progress in Neuropsychopharmacology and Biological Psychiatry. 27, 1007-1012.

26- AKHONDZADEH S., FARAJI H., SADEGHI M., AFKHAM K., FAKHRZADEH H. KAMALIPOUR A. (2003). Double blind comparison of fluoxetine and nortriptyline in the treatment of moderate to severe major depression. Journal of Clinical Pharmacy and Therapeutics. 28, 379-384.

27- AKHONDZADEH S., MAHAJERI H., MOHAMMADI MR., AMINI H. (2003) Ritanserin as an adjunct to lithium and haloperidol for the treatment of medication-naive patients with acute episodes of mania: a double blind and placebo controlled trial. BMC Psychiatry. 19; 3(1): 7.

28- AKHONDZADEH S., ERFANI S., MOHAMMADI MR., TEHRANI-DOOST M., AMINI H. (2004). Cyproheptadine in the treatment of autistic disorder: a double-blind and placebo controlled trial. Journal of Clinical Pharmacy and Therapeutics, 29, 145-150.

29- MOHAMMADI M, KASHANI L, AKHONDZADEH S, SAHIMI IZADIAN E, OHADINIA S. (2004). Efficacy of theophylline compared to methylphenidate for the treatment of attention deficit hyperactivity disorder in children and adolescents: A double blind and randomized trial. . Journal of Clinical Pharmacy and Therapeutics, 29, 139-144.

30- AKHONDZADEH S., MOHAMMADI MR, KHADEMI M. (2004). Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: A double blind and randomized trial [ISRCTN64132371]. BMC Psychiatry. 4: 9.

31-MOHAMMAI MR, GHANIZADEH A, RAHGOZAR M, NOORBALA AA, DAVIDIAN H, MALEK AFZALI H, NAGHAVI HR, YAZDI SA, SABERI SM, MESGARPOUR B, AKHONDZADEH S, ALAGHEBANDRAD J, TEHRANIDOOST M (2004). Prevalence of obsessivecompulsive disorder in Iran. BMC Psychiatry. 4: 2

32- SOLEMANI A, MOAYYERI A, AKHONDZADEH S, SADATSAFAVI M, SHALMANI HY, SOLTANZADEH A. (2004). Frequency of myasthenic crisis in relation to thymectomy in generalized myasthenia gravis: a 17-year experience. BMC Neurology. 4: 12.

33- AKHONDZADEH S, FALLAH-POUR H, AFKHAM K, JAMSHIDI AH, KHALIGHICIGAROUDI F. (2004). Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816]. BMC Complement Altern Med.4: 12.

34- LARIJANI B, KHORAM SHAHI BAYAT M, KHALILI GORGANI M, BANDARIAN F, AKHONDZADEH S, SAJADI SA. (2004). Association between depression and diabetes. German Journal of Psychiatry 7: 62-65.

35. AKHONDZADEH S, SAFARCHERATI A, AMINI H. (2005). Beneficial antipsychotic effects of allopurinol as adjunctive therapy for schizophrenia: A double blind, randomized and placebo controlled trial. Progress in Neuropsychopharmacology and Biological Psychiatry. 29; 253-259.

36- AKHONDZADEH S, TAMACEBI-POUR N, NOORBALA AA, AMINI H, FALLAH POUR H, JAMSHIDI AH, KHANI M. (2005). Crocus sativus L. in the treatment of mild to moderate depression: A double-blind, randomized and placebo controlled trial. Phytotherapy Research. 19, 25-29.

37- NOORBALA AA, AKHONDZADEH S, TAMACEBI-POUR N, Jamshidi AH. (2005). Hydroalcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: A double-blind, randomized pilot trial. Ethnopharmacology. 97; 281-284.

38-AMINI H, AGHAYAN S, JALILI A, AKHONDZADEH S, YAHYAZADEH O, PAKRAVANNEJAD M. (2005). Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind randomized trial. Journal of Clinical Pharmacy and Therapeutics. 30; 133-138.

39- AKHONDZADEH S, MAKKINEJAD K, ALEM, ZM. (2005). Dose psychotic symptoms and cognition impairments improve better with adding lamotrigine to risperidone in chronic schizophrenia? Therapy 2; 399-406.

40- AKHONDZADEH S, RAFIEE-MILAJERDI M, AMINI H, BATHAI FS. and KAMALIPOUR A. (2005) Allopurinol as adjunctive treatment for acute mania in hospitalized bipolar patients. Therapy 2; 739-744.

41- AKHONDZADEH S. and DALIRI HAMPA. (2005) Topiramate prevents ecstasy consumption: A case report. Fundamental and Clinical Pharmacology 19; 601-602

42-ZIAI SA, LARIJANI B, AKHOONDZADEH S, FAKHRZADEH H, DASTPAK A, BANDARIAN F, REZAI A, BADI HN, EMAMI T (2005).Psyllium decreased serum glucose and glycosylated hemoglobin significantly in diabetic outpatients. Ethnopharmacology 102; 202-7.

43- LARIJANI B., TABATABAEI O., SOLTANI A., TAHERI E., PAJOUHI M., BASTANHAGH MA., AKHONDZADEH S., MAHMOODI M., BANDARIAN F., MOHAMMADZADE N., (2005). Comparison of desmopressin (DDAVP) tablet and intranasal spray in the treatment of central diabetes insipidus. DARU 13; 155-159

44- SADATSAFAVI M, MOAYYERI A, SOLTANI A, LARIJANI B, NOURAIE M, AKHONDZADEH S. (2005) Artificial neural networks in prediction of bone density among post-menopausal women. Journal of Endocrinology Investigation 28; 425-431

45- AKHONDZADEH S, MOKHBERI K, AMINI H, LARIJANI B, KASHANI L, HASHEMI L, AK NEJATISAFA, SHAFAEI AR. (2005). Is there a relationship between estrogen serum level and symptoms severity over the menstrual cycle of schizophrenics? Therapy 2; 745-751.

46- AKHONDZADEH S, MOHAMMADI MR, MOMENI F. (2005). Passiflora incarnata in the treatment of attention deficit hyperactivity disorder in children and adolescents: A double blind and randomized trial. Therapy 2; 609-614.

47- DAVOODI G., SADEGHIAN S., AKHONDZADEH S., DARVISH S., ALIDOOSTI M. and AMIRZADEGAN A. (2005). Comparison of specifications, short-term outcome and prognosis of acute myocardial infarction in opium dependent patients and non-dependents. German Journal of Psychiatry 8; 33-37.

48- AKHONDZADEH S, REZAIE F, LARIJANI B, NEJATISAFA AK, KASHANI L, ABBASI SH. (2006). Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia. Schizophrenia Research 84, 405-410. 

49. AKHONDZADEH S, RAFIEE-MILAJERDI M, AMINI H, TEHRANI-DOOSAT M. (2006). Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disorders 8: 485-9.

50- MOSHIRI E, BASTI AA, NOORBALA AA, JAMSHIDI AH, HESAMEDDIN ABBASI S, AKHONDZADEH. (2006) Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: A double-blind, randomized and placebo-controlled trial. Phytomedicine. 13: 607-11.

51- BASTI AA, MOSHIRI E, NOORBALA AA, JAMSHIDI AH, HESAMEDDIN ABBASI S, AKHONDZADEH. (2007). Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: A pilot double-blind randomized trial. Progress in Neoropsychopharmacology and Biological Psychiatry 31:439-42

52- ROKNI-YAZDI H., SOTOUDEH H., AKHONDZADEH S., SOTOUDEH E., ASADI H., SHAKIBA M. (2007). Antidepressant-like effect of magnetic resonance imaging-based stimulation in mice. Progress in Neoropsychopharmacology and Biological Psychiatry 31:503-9

53- AKHONDZADEH S, TABATABAEE M., AMINI H., AHMADI-ABHARI SA., ABBASI SH., BEHNAM B. (2007). Celecoxib as adjunctive therapy in schizophrenia: A double blind, randomized and placebo controlled trial. Schizophrenia Research 90:179-85

54- TOGHA M., AKHONDZADEH S., MOHTAMEDI M. (2007). Allopurinol as adjunctive therapy in intractable epilepsy: A double blind and placebo controlled trial. Archives of Medical Research 38: 313-6

55- RAISI F., HABIBI N., NASEHI AA., AKHONDZADEH S. (2007). Combination of citalopram and nortriptyline in the treatment of severe major depression: a double-blind and placebo- controlled trial. Therapy 4: 187-192.

56- AKHONDZADEH S, TAJDAR H, MOHAMMADI MR, MOHAMADDI M (2008). A doubleblind placebo controlled trial of piracetam added to risperidone in patients with autistic disorders. Child Psychiatry and Human Development 39: 237-245.

57- SADROLSADAT SH, SHOROGHI M, BEHAREN K, FARAHBAKHSH F, AKHONDZADEH S, SHEIKHVATAN M, ABBASI A. (2008). Role of serum potassium changes in anxiety assessment among patients undergoing elective abdominal surgery Minerva Psichiatrica 49: 185-189.

58- AMIRI S, MOHAMMADI MR, MOHAMMADI M, NOUROOZINEJAD GH, KAHBAZI M, AKHONDZADEH S (2008). Modafinil as a treatment for Attention-Deficit/Hyperactivity Disorder in children and adolescents: A double blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry 32: 45-49.

59- AMIRI A, NOORBALA AA, NEJATISAFA AA, GHOREISHI A, DERAKHSHAN MK, KHODAIE-ARDAKANI MR, HAJIAZIM M, RAZNAHAN M, AKHONDZADEH S (2008). Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Human Psychopharmacology 23: 79-86.

60- AGHA-HOSSEINI M, KASHANI L, ALEYASEEN A, GHORESHI A, CH. RAHMANPOUR H. ZARINARA AR, AKHONDZADEH S (2008). Crocus sativus L. (saffron) in the treatment of premenstrual syndromes: A double-blind, randomized and placebo controlled trial British Journal of Gynecology (BJOG) 115: 515-519.

61- SALIMI S, GHOREISHI A, DERAKHSHAN MK, KHODAIE-ARDAKANI MR, MOHAMMADI MR, NOORBALA AA, AHMADI-ABHARI SA, HAJIAZIM M, AKHONDZADEH S (2008). A placebo controlled study of the propentofylline added to risperidone in chronic chizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32: 726-732.

62- KAHBAZI M, GHOREISHI A, RAHIMINEJAD, F, MOHAMMADI MR, AKHONDZADEH S (2009). Modafinil as a treatment for Attention-Deficit/Hyperactivity Disorder in children and adolescents: A double blind, and placebo controlled trial. Psychiatry Research 168:234-7

63- AKHONDZADEH S, GERAMY M. NOOROZIAN M, GHOREISHI A, KARAM GHADIRI N. ABBASI H, REZAZADEH SA. (2008). A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone. Prog Neuropsychopharmacol Biol Psychiatry 32:1810-5.

64- AKHONDZADEH BASTI, A., CHOREISHI, S.A., NOORBALA, A.A., AKHONDZADEH, S.H., REZAZADEH, SH. (2008). Petal and stigma of Crocus sativus L. in the treatment of depression: A pilot double - blind randomized trial. Journal of Medicinal Plants 7: 29-36.

65- AKHONDZADEH S, MOHAMMADI N, NOROOZIAN M, GHOREISHI A, KARAM GHADIRI N. GHOREISHI A, JAMSHIDI AH, FORGHANI S. (2009). Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophrenia Research 107:206-12.

66- AKHONDZADEH S, MALEK-HOSSEINI M, GHOREISHI AM RAZNAHAN M, REZAZADEH SA. (2008). Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 32:1879-83.

67- AKHONDZADEH S, JAFARI S, RAISI F, NASEHI AA, GHOREISHI A, SALEHI B, MOHEBBI-RASA S, RAZNAHAN M, KAMALIPOUR A. (2009). Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 26:607-11.

68- GHANIZADEH A, MANSOORI Y, ASHKANI H, FALLAHZADEH MH, DERAKHSHAN A, SHOKRPOUR N, AKHONDZADEH S. (2009). Major depressive disorder in children and adolescents after renal transplantation. Transplant Proc 41:1627-9.

69- AKHONDZADEH S, SHAFIEE SABET M, HARIRCHIAN MH, TOGHA M, CHERAGHMAKANI H, RAZEGHI S, HEJAZI SS, YOUSEFI MH, ALIMARDANI R, JAMSHIDI A, REZAZADEH SA, YOUSEFI A, ZARE F, MORADI A, VOSSOUGHI A. (2009). A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-tomoderate Alzheimer's disease. Psychopharmacology (Berl). 2010; 207: 637-643

70- SALEHI B, IMANI R, MOHAMMADI MR, FALLAH J, MOHAMMADI M, GHANIZADEH A, TASVIECHI AA, VOSSOUGHI A, REZAZADEH SA, AKHONDZADEH S. (2010). Ginkgo biloba for Attention-Deficit/Hyperactivity Disorder in children and adolescents: A double blind, randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry., 34, 76-80 10

71-: AKHONDZADEH S, FALLAH J, MOHAMMADI MR, IMANI R, MOHAMMADI M, SALEHI B, GHANIZADEH A, RAZNAHAN M, MOHEBBI-RASA S, REZAZADEH SA, FORGHANI S. (2010). Double-blind placebo-controlled trial of pentoxifylline added to risperidone: Effects on aberrant behavior in children with autism. Prog Neuropsychopharmacol Biol Psychiatry., 34, 32-36

72- ABBASI SH, BEHPORNIA H, GHOREISHI A, SALEHI B, RZANAHAN M, REZAZADEH SA, REZAEI F, AKHONDZADEH S. (2010). The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: A double-blind randomized placebo-controlled trial. Schizophr Res., 116, 101-106 B. Editorial

73- AKHONDZADEH S. (1998). The glutamate hypothesis of schizophrenia. Journal of Clinical Pharmacy and Therapeutics. 23, 243-246.

C. Review Article

74- AKHONDZADEH S. (1999). Hippocampal synaptic plasticity and cognition. Journal of Clinical Pharmacy and Therapeutics., 24, 241-248.

75- AKHONDZADEH S. (2001) The 5-HT hypothesis of schizophrenia. IDRUGS., 4, 295-300.

76- AKHONDZADEH S. & MOHAMMADI M.R. (2001). Schizophrenia: etiology and

pharmacotherapy. IDRUGS. 4, 1167-1172.

77- AKHONDZADEH S. & Noroozian M. (2002). Alzheimer’s disease: Pathophysiology and pharmacotherapy. IDRUGS. 5 , 1062-1069.

78- AKHONDZADEH S. (2006). Pharmacotherapy of schizophrenia: The past, present and future. Current Drug Therapy. 1, 1-7.

79- AKHONDZADEH S. and ABASSI SH. (2006). Herbal medicine in the treatment of Alzheimer’s disease. American Journal of Alzheimer’s Disease and Other Dementia  21: 113-8.

80- NOORBALA AA., AKHONDZADEH S. (2006). Attention-deficit/hyperactivity disorder: etiology and pharmacotherapy. Archives of Iranian Medicine 9:374-80

81- ABBASI SH, AFKHAM K, AKHONDZADEH S. (2006). Antipsychotic Drugs and Sudden Death. The Journal of Tehran University Heart Center 1: 5-11.

82- MALEKI J. AKHONDZADEH S. (2007). Cardiovascular Effects of Antidepressants and Mood Stabilizers. The Journal of Tehran University Heart Center 2: 133-136. 11

83- MOHAMMADI MR, AKHONDZADEH S. (2007). Attention-deficit/hyperactivity disorder: etiology and pharmacotherapy. Expert Review in Neuroterapeutics 7: 195-201

84- MOHAMMADI MR, AKHONDZADEH S. (2007). Autism spectrum disorders: etiology and pharmacotherapy. Current Drug Therapy 2, 97-103.

85- BATHAEI FS, AKHONDZADEH S. (2008). Cardiovascular Effects of Allium Sativum (Garlic): An Evidence-Based Review. Journal of Tehran University Heart Center 3: 5-10.

86- KAMALIPOUR, M., AKHONDZADEH, S.H., REZAZADEH, SH. (2008). Herbal medicines in the treatment of depression and anxiety. Journal of Medicinal Plants 7: 1-7.

87- KASHANI L, AKHONDZADEH S. (2009). Herbal medicine and women's mental health. Journal of Medicinal Plants 8: 1-6.

88- AKHONDZADEH S, ABBASI SH. (2009). The Meeting of Psychiatry and Humanities: An Overview 2: 5 D. Commentary

89- AKHONDZADEH S. (2003). Hydroxyzine may be safe and effective in generalized anxiety disorder. Evidence Based Mental Health, 6, 91. E. Research Letter

90- SALMASI FB, JAZAYERI M, GHAELI P, HASHEMIAN F, AKHONDZADEH S, RAISI F, HOSSEINI SH, SETAREH MJ, KHAVIDAKI SD. (2009). Comparing the effects of high-dose vitamin E with those of placebo on insulin resistance in patients with schizophrenia treated with olanzapine. J Clin Psychopharmacol29:182-3

91- GHANIZADEH A, AKHONDZADEH S. (2009) Attention deficit hyperactivity disorder in prison. J Am Acad Psychiatry Law 37:278. F. Abstracts (in journals)

92 AKHONDZADEH, S. & STONE, T.W. (1994). Enhancement by muscimol of adenosine effects on population spikes in the presence of barium. Canadian J. Physiol. Pharmacol., 72, 503.

93- AKHONDZADEH, S. & STONE, T.W. (1994). Enhancement by muscimol of adenosine effects on hippocampal population spikes, Br. J. Pharmacol., 112, 612P.

94- AKHONDZADEH, S. & STONE, T.W. (1994). Suppression by DIDS of an interaction between adenosine and muscimol in the hippocampus. Br. J. Pharmacol., 113, 106P. 12

95- AKHONDZADEH, S. & STONE, T.W. (1995). neurosteroids enhance muscimol and adenosine potentiation in the presence of barium. Br. J. Pharmacol. 114, 292P.

96- AKHONDZADEH, S. & STONE, T.W. (1995) Neurosteroids potentiate GABA and adenosine inhibition of hippocampal evoked potentials. Br. J. Pharmacol. 114, 293P.

97- AKHONDZADEH, S., SHABESTARI, O.L. & FARZANEHGAN, Z.M. (2000). Potentiation of muscimol-induced long-term depression by diazepam and chlordiazepoxide. Br. J. Pharmacol., 129, 163.

98- AKHONDZADEH S., MOHAMMADI, M.R., DAVARI-ASHTIANI, R., AMININOOSHABADI, H. & FARZANEHGAN, Z.M. (2000). Cyproheptadine in the treatment of chronic schizophrenia: implications for the 5-HT hypothesis of schizophrenia. Br. J. Clin. Pharmacol., 49, 491.

99- AKHONDZADEH S., NOORBALA, A.A., DAVARI-ASHTIANI, R., AMINI-NOOSHABADI, H. & SHABESTARI, O.L. (2000). Piracetam in the treatment of schizophrenia: a double-blind, placebo-controlled study. Br. J. Clin. Pharmacol. 49, 507.

100- AKHONDZADEH S., AHMADI-ABHARI S.A., ASSADI S.M. & SHABESTARI O.L. (2000). Double-blind randomized controlled trial of baclofen in the treatment of opiates withdrawal. Br. J. Clin. Pharmacol. 51, 364P.

101- AKHONDZADEH S. KHASHANI L. and MOBASERI M. (2002). Potentiation of Muscimolinduced long-term depression by benzodiazepines but not zolpidem. Br. J. Pharmacology. 135, U37.

102- AKHONDZADEH S., TAVAKOLIAN R., DAVARI-ASHTIANI R. and AMININOOSHABADI H. (2002). Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind randomized and controlled trial. Br. J. Clin. Pharmacology, 54, 39P.

103- AKHONDZADEH S., MOJTAHEDZADEH V. and MIRSEPASSI G.R. (2002). Diazoxide in the treatment of schizophrenia: a novel application of potassium channel openers in the CNS disorders. Br. J. Clin. Pharmacology54, 40P.

104- AKHONDZADEH S., NOROOZIAN M., MOHAMMADI MR., OHADINIA S. & MOIN M.(2003). Effects of a fixed dose of Melissa officinalis extract in Alzheimer’s disease: a randomized, placebo controlled trial. British Journal of Clinical Pharmacology. 55, 443-445

105- AKHONDZADEH S., NEJATISAFA AA. & AMINI H. (2003). A clinical trial of adjunctive estrogen treatment in women with chronic schizophrenia: a double blind and placebo controlled study. Proceeding of the British Pharmacological Society at http://www.pa2online/Vol1Issue2abst021.html

106- AKHONDZADEH S., FARAJI H. & SADEGHI M. (2003) Comparison of fluoxetine and nortriptyline in the treatment of moderate to severe major depression: A double blind and randomized trial. Proceeding of the British Pharmacological Society at http://www.pa2online/Vol1Issue2abst023.html

107- AKHONDZADEH S., NOROOZIAN M. & MOHAMMADI MR. (2003) Salvia officinalis extract in the treatment of mild to moderate Alzheimer’s disease: a double blind and placebo13 controlled trial. Proceeding of the British Pharmacological Society at http://www.pa2online/Vol1Issue2abst022.html

108- AKONDZADEH S., MOHAMMADI MR., MAHAJERI H., AMINI H., KASHANI L. (2004) Ritanserin as an adjunct to lithium and haloperidol for the treatment of patients with acute mania: A double blind and placebo controlled trial. British Journal of Clinical Pharmacology. 57, 670.

109- AKONDZADEH S., MOHAMMADI MR., Erfani S., Tehranidoost M., Amini H., Kashani L. (2004). A clinical trial of adjunctive cyproheptadine in the treatment of autistic disorder: A doubleblind and placebo controlled trial British Journal of Clinical Pharmacology. 57, 674.

110- NOROOZIAN M, AKHONDZADEH S, MOHAMMADI MR., OHADINIA S (2004). Effects of a fixed dose of Melissa officinalis extract in Alzheimer’s disease: a randomized, placebo controlled trial. International Psychogeriaterics. 15, 216.

111- AKHONDZADEH S, MILAJERDI MR, AMINI H, MOINOLGHORBAEI M. (2005). A doubleblind, randomized, placebo-controlled study of allopurinol as adjunctive treatment for acute mania in hospitalized bipolar patients. British Journal of Clinical Pharmacology 59; 634-634.

112- AKHONDZADEH S, NOORBALA AA, TAHMACEBO POUR N, KASHANI L. (2005). Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo controlled trial. British Journal of Clinical Pharmacology 59; 630-630.

113- AKHONDZADEH S, MOHAMMADI MR, MOMENI F, MOSHAVER A.. (2005). Passiflora incarnata in the treatment of attention deficit hyperactivity disorder in children and adolescents: A double blind and randomized trial. Proceeding of British Pharmacological Society.

114- AKHONDZADEH S, MAKKINEJAD K, ALEM, ZM, MOINOLGHORBAEI M. (2005). Is there an improvement in psychotic symptoms and cognition impairments with the addition of lamotrigine to risperidone in chronic schizophrenia? Proceeding of British Pharmacological Society.

115- AKHONDZADEH S, MOKHEBERI K, KASHANI L. (2006). Is there a relationship between estrogen serum concentration and symptom severity throughout the menstrual cycle of patients with schizophrenia? British Journal of Clinical Pharmacology 61: 619-619.

116- AKHONDZADEH S, TABATABAEE M, AMINI H, AHMADI-ABHARI S A (2007). A clinical trial of adjunctive celecoxib treatment in patients with chronic schizophrenia: a double-blind and placebo controlled trial. British Journal of Clinical Pharmacology 63: 774-774.

117- AKHONDZADEH S, TAGDAR H, MOHAMMADI MR (2007). Piracetam added to risperidone in patients with autistic disorder: a double-blind placebo controlled trial. British Journal of Clinical Pharmacology 63: 777-777.

118- AKHONDZADEH SM AMIRI A, KASHANI L. (2008) .A placebo controlled trial of the selegiline added to risperidone in chronic schizophrenia. British Journal of Clinical Pharmacology 65: 981-981

119- AKHONDZADEH S, MALEK-HOSSEINI, M (2009). Effect of ritanserin on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial. British Journal of Clinical Pharmacology 68: 304. 14

120- AKHONDZADEH S, SALIMI S (2009). A placebo controlled trial of propentofylline added to risperidone in chronic schizophrenia. British Journal of Clinical Pharmacology 68: 303-304.

G: Abstracts in Proceedings

AKHONDZADEH S., FARAJI H. & SADEGHI M. (2003) Comparison of fluoxetine and nortriptyline in the treatment of moderate to severe major depression: A double blind and randomized trial. In VII

World Conference on Clinical Pharmacology and Therapeutics IUPHAR- Division of Clinical Pharmacology. Florence, Italy, 2000 

AKHONDZADEH S., NOROOZIAN M. & MOHAMMADI MR. (2003) Salvia officinalis extract in the treatment of mild to moderate Alzheimer’s disease: a double blind and placebo-controlled trial. In VII World Conference on Clinical Pharmacology and Therapeutics IUPHAR- Division of Clinical Pharmacology. Florence, Italy, 2000

H. Book:

Low-Cost Approaches to Promote Physical and Mental Health: Theory Research and Practice. Edited by Luciano L’Abate. Chapter 6: Herbal Medicine in the treatment of psychiatric and neurological Disorders. Springer 2007, New York, USA.

Encyclopedia of Iranian Medicinal Plants (in Persian). Arjomand Press, 2000, Tehran, Iran.

Principal of Research and Scientific Writing in Medical Sciences (in Persian). Salemi Press, 2003, Tehran, Iran.

Gender Differences and Schizophrenia: Evidence for Estrogen Hypothesis (in Persian). Tehran University of Medical Sciences Press, 2005, Tehran, Iran.

I. Other Communications:

A number of full papers, oral presentations and lectures in Iranian journals and congress-seminars (more than 100).

Teaching Profile:

A- Teaching Clinical neuroscience, Addiction, Research methodology, Clinical Psychopharmacology to medical students, residents of psychiatry and fellow of child and adolescent psychiatry.

B- Teaching scientific writing at Tehran University of Medical Sciences, all Iranian medical schools and many courtiers in the Middle East region.

C- Supervising more than 50 theses for MD and Pharm.D. degree, Board of Psychiatry or Child psychiatry and Ph.D. degree so far that all of them have been published in international journals